Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015364 | 0.84 | EPHX2 (0.42) | CNR2EPHX2SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4010916 | 0.82 | CNR2 (0.33) | CNR2EPHX2SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4017277 | 0.82 | GRIN2D (0.33) | CNR2EPHX2SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4009862 | 0.82 | EPHX2 (0.51) | CNR2EPHX2 | |
| SCHEMBL4012362 | 0.79 | SMN1; SMN2 (0.33) | CNR2EPHX2SMN1; SMN2MAPTDPP4 | |
| SCHEMBL4017218 | 0.79 | EPHX2 (0.32) | CNR2EPHX2SMN1; SMN2MAPTDPP4 | |
| SCHEMBL4010078 | 0.79 | CNR2 (0.34) | CNR2EPHX2SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL4010390 | 0.79 | EPHX1 (0.31) | CNR2ALDH1A1TSHR | |
| SCHEMBL4011003 | 0.79 | EPHX2 (0.38) | EPHX2KMT2A | |
| SCHEMBL3226887 | 0.78 | CNR2 (0.33) | CNR2EPHX2SMN1; SMN2MAPTDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513302-B2 | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-20 | — | — | US | claimed |
| EP-1904050-B1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE CARDIOMYOPATHY | UNIV CALIFORNIA (US) | 2012-11-14 | — | — | EP | claimed |
| US-8242170-B2 | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-14 | — | — | US | claimed |
| US-20110269831-A1 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-03 | — | — | US | claimed |
| US-20100317733-A1 | USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-16 | — | — | US | claimed |
| US-20090216318-A1 | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-08-27 | — | — | US | claimed |
| US-20080279912-A1 | Use of Cis-Epoxyeicosatrienoic Acids And Inhibitors of Soluble Epoxide Hydrolase to Alleviate Eye Disorders | REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2008-11-13 | — | — | US | claimed |
| EP-1909796-A1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO ALLEVIATE EYE DISORDERS | The Regents of the University of California (US) | 2008-04-16 | — | — | EP | claimed |
| EP-1904050-A2 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE CARDIOMYOPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2006133257-A9 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE CARDIOMYOPATHY | UNIV CALIFORNIA (US) | 2007-05-10 | — | — | WO | claimed |
| WO-2007009001-A1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO ALLEVIATE EYE DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-18 | — | — | WO | claimed |
| EP-1737443-A2 | USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | The Regents of the University of California (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2006133257-A2 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE CARDIOMYOPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-14 | — | — | WO | claimed |
| US-20060148744-A1 | Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce damage from stroke | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-07-06 | — | — | US | claimed |
| WO-2005094373-A2 | CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND METHODS TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-13 | — | — | WO | claimed |
| US-20050222252-A1 | Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-06 | — | — | US | claimed |
| EP-1575489-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2003061597-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-07-31 | — | — | WO | claimed |
| US-20030139469-A1 | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-07-24 | — | — | US | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11690837-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230071934-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-03-09 | — | — | US | disclosed |
| US-11564914-B2 | Methods of treating bone loss | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| US-11123311-B2 | Methods of treating mental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| WO-2021127517-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| EP-2846825-B1 | TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS | UNIV CALIFORNIA (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10813894-B2 | Methods of inhibiting pain | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200317813-A1 | TREATMENT AND DIAGNOSIS OF NON-PROLIFERATIVE DIABETIC RETINOPATHY | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2020-10-08 | — | — | US | disclosed |
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-10-01 | — | — | US | disclosed |
| WO-2020132522-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-06-25 | — | — | WO | disclosed |
| US-10383835-B2 | Treatment of inflammatory disorders in non-human mammals | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-20 | — | — | US | disclosed |
| US-10369141-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3463470-A1 | TREATMENT AND DIAGNOSIS OF NON-PROLIFERATIVE DIABETIC RETINOPATHY | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2019-04-10 | — | — | EP | disclosed |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180125803-A1 | METHODS OF INHIBITING PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-10 | — | — | US | disclosed |
| WO-2017214394-A2 | METHODS OF TREATING BONE LOSS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017202957-A1 | TREATMENT AND DIAGNOSIS OF NON-PROLIFERATIVE DIABETIC RETINOPATHY | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017120012-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017007548-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-12 | — | — | WO | disclosed |
| WO-2016133788-A1 | METHODS OF INHIBITING PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-08-25 | — | — | WO | disclosed |
| US-20160008342-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-01-14 | — | — | US | disclosed |
| US-9119837-B2 | Use of sEH inhibitors as analgesics | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-01 | — | — | US | disclosed |
| EP-2846825-A1 | TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS | The Regents of The University of California (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013138118-A1 | TREATMENT OF INFLAMMATORY DISORDERS IN NON-HUMAN MAMMALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-09-19 | — | — | WO | disclosed |
| US-8513302-B2 | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-20 | — | — | US | disclosed |
| US-8399425-B2 | Alleviating neuropathic pain with EETs and sEH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-19 | — | — | US | disclosed |
| US-20130065936-A1 | MODULATION OF BIOACTIVE EPOXY-FATTY ACID LEVELS BY PHOSPHODIESTERASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130045172-A1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO TREAT CONDITIONS MEDIATED BY PBR, CB2, and NK2 RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-21 | — | — | US | disclosed |
| EP-1904050-B1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE CARDIOMYOPATHY | UNIV CALIFORNIA (US) | 2012-11-14 | — | — | EP | disclosed |
| US-8263651-B2 | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-09-11 | — | — | US | disclosed |
| US-8242170-B2 | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-14 | — | — | US | disclosed |
| EP-1931201-B1 | USE OF SEH INHIBITORS AS ANALGESICS | UNIV CALIFORNIA (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120046251-A1 | INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT OR PREVENT NIACIN-INDUCED FLUSHING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011143607-A1 | MODULATION OF BIOACTIVE EPOXY-FATTY ACID LEVELS BY PHOSPHODIESTERASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110269831-A1 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110230504-A1 | ALLEVIATING DISORDERS WITH COMBINING AGENTS THAT INCREASE EPOXYGENATED FATTY ACIDS AND AGENTS THAT INCREASE cAMP | The Regents Of The University Of California Office Of Technology (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2334180-A1 | ALLEVIATING DISORDERS WITH COMBINING AGENTS THAT INCREASE EPOXYGENATED FATTY ACIDS AND AGENTS THAT INCREASE CAMP | The Regents of the University of California (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011066567-A1 | METHODS OF TREATING DIABETES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-06-03 | — | — | WO | disclosed |
| US-7951831-B2 | Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100317733-A1 | USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100286222-A1 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO SYNERGIZE ACTIVITY OF COX AND 5-LOX INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100267807-A1 | ALLEVIATING NEUROPATHIC PAIN WITH EETS AND SEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | US | disclosed |
| WO-2010117951-A1 | INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT OR PREVENT NIACIN-INDUCED FLUSHING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-2219450-A1 | ALLEVIATING NEUROPATHIC PAIN WITH EETS AND SEH INHIBITORS | The Regents of the University of California (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100074852-A1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO TREAT CONDITIONS MEDIATED BY PBR, CB2, AND NK2 RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-03-25 | — | — | US | disclosed |
| WO-2010030851-A1 | ALLEVIATING DISORDERS WITH COMBINING AGENTS THAT INCREASE EPOXYGENATED FATTY ACIDS AND AGENTS THAT INCREASE cAMP | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-18 | — | — | WO | disclosed |
| EP-2124928-A1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO TREAT CONDITIONS MEDIATED BY PBR, CB2, AND NK2 RECEPTORS | The Regents of The University of California (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | disclosed |
| US-20090216318-A1 | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-08-27 | — | — | US | disclosed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009062073-A1 | ALLEVIATING NEUROPATHIC PAIN WITH EETS AND SEH INHIBITORS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | WO | disclosed |
| EP-1765311-A4 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | UNIV CALIFORNIA (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20090018092-A1 | Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-01-15 | — | — | US | disclosed |
| US-20080279912-A1 | Use of Cis-Epoxyeicosatrienoic Acids And Inhibitors of Soluble Epoxide Hydrolase to Alleviate Eye Disorders | REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080249055-A1 | Use of Seh Inhibitors as Analgesics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-09 | — | — | US | disclosed |
| US-20080188554-A1 | METHODS OF TREATING AVIAN HYPERTENSION | REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008073130-A1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO TREAT CONDITIONS MEDIATED BY PBR, CB2, AND NK2 RECEPTORS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1931201-A2 | USE OF SEH INHIBITORS AS ANALGESICS | The Regents of the University of California (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1909796-A1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO ALLEVIATE EYE DISORDERS | The Regents of the University of California (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1904050-A2 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE CARDIOMYOPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1845976-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO SYNERGIZE ACTIVITY OF COX AND 5-LOX INHIBITORS | The Regents of The University of California (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006133257-A9 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE CARDIOMYOPATHY | UNIV CALIFORNIA (US) | 2007-05-10 | — | — | WO | disclosed |
| EP-1765311-A2 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007022509-A2 | USE OF SEH INHIBITORS AS ANALGESICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007009001-A1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO ALLEVIATE EYE DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-1737443-A2 | USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | The Regents of the University of California (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006133257-A2 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE CARDIOMYOPATHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006086108-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO SYNERGIZE ACTIVITY OF COX AND 5-LOX INHIBITORS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060178347-A1 | Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-10 | — | — | US | disclosed |
| US-20060148744-A1 | Use of cis-epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce damage from stroke | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-07-06 | — | — | US | disclosed |
| WO-2005094373-A2 | CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND METHODS TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222252-A1 | Use of cis-Epoxyeicosantrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005089380-A2 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-29 | — | — | WO | disclosed |
| EP-1575489-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2003061597-A2 | USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT VASCULAR SMOOTH MUSCLE CELL PROLIFERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030139469-A1 | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-07-24 | — | — | US | disclosed |
| US-20030139469-A1 | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (30 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306232-A1 | METHODS OF TREATING BONE LOSS | EPHX1, NCEH1, SOST | CNR2 1904/4885EPHX2 4/4885SMN1; SMN2 4135/4885 |
| US-20110269831-A1 | REDUCING NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND EPOXYEICOSANOIDS | EPHX1, EPHX2, NCEH1 | CNR2 918/4885EPHX2 2/4885SMN1; SMN2 4070/4885 |
| US-20100267807-A1 | ALLEVIATING NEUROPATHIC PAIN WITH EETS AND SEH INHIBITORS | EPHX1, FAAH, EPHX2 | CNR2 58/4885EPHX2 3/4885SMN1; SMN2 1026/4885 |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | CNR2 363/4885EPHX2 51/4885SMN1; SMN2 742/4885 |
| US-20080249055-A1 | Use of Seh Inhibitors as Analgesics | EPHX1, FAAH, EPHX2 | CNR2 358/4885EPHX2 3/4885SMN1; SMN2 3995/4885 |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | EPHX1, ECE1, LIPG | CNR2 1318/4885EPHX2 5/4885SMN1; SMN2 4793/4885 |
| US-20160008342-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | ELOVL1, ELOVL3, IL2 | CNR2 753/4885EPHX2 127/4885SMN1; SMN2 935/4885 |
| US-20110230504-A1 | ALLEVIATING DISORDERS WITH COMBINING AGENTS THAT INCREASE EPOXYGENATED FATTY ACIDS AND AGENTS THAT INCREASE cAMP | FAAH, EPHX1, FAAH2 | CNR2 67/4885EPHX2 4/4885SMN1; SMN2 2698/4885 |
| US-20080279912-A1 | Use of Cis-Epoxyeicosatrienoic Acids And Inhibitors of Soluble Epoxide Hydrolase to Alleviate Eye Disorders | EPHX1, PTGES, PTGS1 | CNR2 413/4885EPHX2 5/4885SMN1; SMN2 4699/4885 |
| US-20180200244-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | ELOVL1, ELOVL3, IL2 | CNR2 753/4885EPHX2 127/4885SMN1; SMN2 935/4885 |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | CNR2 68/4885EPHX2 4/4885SMN1; SMN2 4001/4885 |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | FABP7, ADH1B, ELOVL1 | CNR2 363/4885EPHX2 51/4885SMN1; SMN2 742/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | CNR2 572/4885EPHX2 10/4885SMN1; SMN2 417/4885 |
| US-20180125803-A1 | METHODS OF INHIBITING PAIN | ATP2A3, ATP2A1, ATP2A2 | CNR2 88/4885EPHX2 503/4885SMN1; SMN2 313/4885 |
| US-11690837-B2 | Methods of improving cell-based therapy | ELOVL1, ELOVL3, IL2 | CNR2 753/4885EPHX2 127/4885SMN1; SMN2 935/4885 |
| US-11564914-B2 | Methods of treating bone loss | EPHX1, NCEH1, SOST | CNR2 1904/4885EPHX2 4/4885SMN1; SMN2 4135/4885 |
| US-20090018092-A1 | Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids | EPHX1, EPHX2, NCEH1 | CNR2 918/4885EPHX2 2/4885SMN1; SMN2 4070/4885 |
| US-10813894-B2 | Methods of inhibiting pain | ATP2A3, ATP2A1, ATP2A2 | CNR2 88/4885EPHX2 503/4885SMN1; SMN2 313/4885 |
| US-20230071934-A1 | NOVEL USES | SMPD1, PDE4A, PDE7A | CNR2 1348/4885EPHX2 534/4885SMN1; SMN2 292/4885 |
| US-20120046251-A1 | INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO INHIBIT OR PREVENT NIACIN-INDUCED FLUSHING | EPHX1, NCEH1, FAAH | CNR2 442/4885EPHX2 6/4885SMN1; SMN2 4298/4885 |
| US-20080188554-A1 | METHODS OF TREATING AVIAN HYPERTENSION | EPHX1, ERH, EPHX2 | CNR2 3221/4885EPHX2 3/4885SMN1; SMN2 4750/4885 |
| US-20100074852-A1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO TREAT CONDITIONS MEDIATED BY PBR, CB2, AND NK2 RECEPTORS | CNR2, EPHX2, CNR1 | CNR2 1/4885EPHX2 2/4885SMN1; SMN2 3597/4885 |
| US-10369141-B2 | Methods of improving cell-based therapy | ELOVL1, ELOVL3, IL2 | CNR2 753/4885EPHX2 127/4885SMN1; SMN2 935/4885 |
| US-11123311-B2 | Methods of treating mental disorders | FAAH, EPHX1, FAAH2 | CNR2 68/4885EPHX2 4/4885SMN1; SMN2 4001/4885 |
| US-20100317733-A1 | USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS | EPHX1, EPHX2, LTA4H | CNR2 1586/4885EPHX2 2/4885SMN1; SMN2 3459/4885 |
| US-20180185309-A1 | METHODS AND COMPOSITIONS FOR TREATING NEPHROPATHY | GLS, REN, SLC5A2 | CNR2 4040/4885EPHX2 3353/4885SMN1; SMN2 693/4885 |
| US-20130065936-A1 | MODULATION OF BIOACTIVE EPOXY-FATTY ACID LEVELS BY PHOSPHODIESTERASE INHIBITORS | PTGIS, PDE2A, PDE3B | CNR2 510/4885EPHX2 45/4885SMN1; SMN2 3870/4885 |
| US-20130045172-A1 | USE OF CIS-EPOXYEICOSATRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO TREAT CONDITIONS MEDIATED BY PBR, CB2, and NK2 RECEPTORS | CNR2, EPHX2, CNR1 | CNR2 1/4885EPHX2 2/4885SMN1; SMN2 3597/4885 |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | CNR2 68/4885EPHX2 4/4885SMN1; SMN2 4001/4885 |
| US-10383835-B2 | Treatment of inflammatory disorders in non-human mammals | EPHX1, SERPINB1, PTGES | CNR2 259/4885EPHX2 13/4885SMN1; SMN2 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.